Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200625 · ClinicalTrials.gov registry record
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
A clinical trial, sponsored by University of Miami.
- Completed
- Registry status
- 80
- Enrollment target
NCT04200625 is a clinical trial that has completed, run by University of Miami. The registered enrollment target is 80 participants.
The verdict
NCT04200625 has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-09-24 |
| Est. Completion | 2019-12-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04200625
The ClinicalTrials.gov registry entry for NCT04200625 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04200625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04200625 about?
NCT04200625 is a clinical study titled "Semaglutide vs Dulaglutide on Epicardial Adipose Tissue". Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists...
What is the current status of trial NCT04200625?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2019-09-24. Estimated completion is 2019-12-09.
Who is sponsoring clinical trial NCT04200625?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.